BackgroundMedication therapy is a cornerstone for the primary and secondary prevention of cardiovascular diseases (CVD), yet values and preferences regarding medication use remain unclear. ObjectiveThis study aims to explore the values and preferences of medication use in patients for the primary and secondary prevention of CVD. MethodsThis study employed an explanatory sequential mixed methods design. From November 2021 to January 2022, patients meeting the criteria for primary and secondary prevention of CVD were screened at West China Hospital of Sichuan University and Yulin Community Health Service Center in Wuhou District, Chengdu, using stratified purposive sampling for interviews. Qualitative data were collected through focus group interviews to understand the behavior, values, and preferences related to medication use among the participants. The interview content was coded and categorized using MAXQDA 2020, then further sorted, analyzed, and themes were extracted using Colaizzi's seven-step analysis method. Following the qualitative research, a quantitative questionnaire was developed based on the themes identified from the interviews. From November 2022 to February 2023, patients meeting the criteria for primary and secondary prevention of CVD were conveniently sampled from the cardiology, endocrinology, nephrology, and neurology outpatient clinics at West China Hospital of Sichuan University and Yulin Community Health Service Center in Wuhou District, Chengdu. After signing informed consent, the participants' values and preferences regarding medication use were quantitatively analyzed. ResultsThe qualitative study included 21 participants for focus group interviews, yielding four themes: (1) cognition and behavior towards medication; (2) barriers to medication use; (3) facilitators of medication use; and (4) needs for medical services. In the quantitative study, 186 valid questionnaires were returned, yielding a 93.5% response rate. The results indicated common missed doses, and further confirmed the social stigmatization and the burden of medication use identified in the qualitative study. Despite the heterogeneity in medication preferences, participants generally preferred fewer types of drugs and lower frequencies of medication, and were averse to injectable formulations. ConclusionIn clinical practice for the primary and secondary prevention of CVD, the use of compound preparation could be increased, and medication regimens could be integrated with patients' daily lives and work to reduce the medication burden. Additionally, it is important to actively address patients' misconceptions and inappropriate behaviors regarding diseases and medications to improve medication compliance.